Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept

References

• Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes. Ann Rheum Dis. 1988;47(4):313–22
   PubMed Web of Science ®Google Scholar
• Scott DL, Symmons DP, Coulton BL, Popert AJ. Long term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987;1(8542):108–11.
   Google Scholar
• Shiozawa K, Shiozawa S, Shimizu S, Fujita T. Fibronectin on the surface of articular cartilage in rheumatoid arthritis. Arthritis Rheum. 1984;27(6):615–22.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Landewe R, Bruyn GAW, Cantagrel A, Landewé R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(12):3928–39.
   PubMed Web of Science ®Google Scholar
• Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol. 2009; 28(4):413–9.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Deighton C, Watson KD, Symmons DPM, Lunt M. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford). 2009;48(10):1323–7.
   PubMed Web of Science ®Google Scholar
• Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis. 2010;69(1):126–31.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Takeuchi T, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17(1):28–32.
   PubMedGoogle Scholar
• Smolen S, van der Heijde MFM, Clair EW, Paul Emery P, Bala M, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab; Results from the ASPIRE Trial. Arthritis Rheum. 2006;54(3):702–10.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–19.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Kishimoto T, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371(9617):998–1006.
   PubMed Web of Science ®Google Scholar
• Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Sumida T, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med. 2007;46(11):771–4.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M, Giorgio ED, Alten R, Moreland LW, et al. Treatment of rheumatoid arthritis by selective inhibition of t-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907–15.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Matsubara T, Nitobe T, Suematsu E, Ohta S, Miyasaka N, et al. Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod Rheumatol. 2013;23(2):226–35.
   PubMed Web of Science ®Google Scholar
• Durez P, Malghem J, Toukap AN, Depresseux G, Lauwerys BR, Verschueren P, et al. Treatment of early rheumatoid arthritis; a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56(12):3919–27.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Huizinga TWJ, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43–50.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Troum O, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014;73(5):810–6.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Durez P, Rieke E, Alten RE, Burmester GR, Tak PP, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013;72(8):1287–94.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Sumida T, et al. A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. Mod Rheumatol. 2009;19(4):358–65.
   PubMed Web of Science ®Google Scholar
• McQueen F, Lassere M, Edmonds J, Conaghan P, Peterfy C, Østergaard M, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Summary of OMERACT 6 MR imaging module. J Rheumatol. 2003;30(6):1387–92.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73: 492–509.
   PubMed Web of Science ®Google Scholar
• Freeston JE, Brown AK, Hensor EM, Emery P, Conaghan PG. Extremity magnetic resonance imaging assessment of synovitis (without contrast) in rheumatoid arthritis may be less accurate than power Doppler ultrasound. Ann Rheum Dis. 2008;67(9):1351.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–74.
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Edwards CJ, Østergaard M, van der Heijde D, Balint PV, Conaghan PG, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72():804–14.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Østergaard M, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis (CIMESTRA). Ann Rheum Dis. 2009;68(3):384–90.
   PubMed Web of Science ®Google Scholar